Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sonnet Biotherapeutics Holdings Inc
(NQ:
SONN
)
1.770
+0.010 (+0.57%)
Streaming Delayed Price
Updated: 3:46 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Sonnet Biotherapeutics Holdings Inc
< Previous
1
2
Next >
Sonnet BioTherapeutics Announces Webcast to Discuss Interim Data from the Company’s Phase 1 Dose-Escalation Trials of SON-1010 on November 2, 2022
November 01, 2022
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product Candidates
October 31, 2022
Via
ACCESSWIRE
Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
October 04, 2022
Via
ACCESSWIRE
Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company's Business Advisory Committee
September 26, 2022
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010
September 21, 2022
Via
ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2022 Third Quarter Business and Earnings Update
August 15, 2022
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces 1-for-14 Reverse Stock Split
September 16, 2022
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy
July 22, 2022
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy
July 22, 2022
PRINCETON, NJ / ACCESSWIRE / July 22, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a Phase...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers
July 21, 2022
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers
July 21, 2022
PRINCETON, NJ / ACCESSWIRE / July 21, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a second...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition
June 09, 2022
PRINCETON, NJ / ACCESSWIRE / June 9, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs,...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum
June 02, 2022
PRINCETON, NJ / ACCESSWIRE / June 2, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs,...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update
May 10, 2022
- IND for SON-1010 cleared by FDA with first patient dosed in trial for advanced solid tumors - SON-080 on track to begin clinical studies by mid-2022 - Preclinical data for SON-1010, SON-1210, and...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Exposures
Product Safety
Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors
April 13, 2022
PRINCETON, NJ / ACCESSWIRE / April 13, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that dosing has...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting
April 08, 2022
PRINCETON, NJ / ACCESSWIRE / April 8, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that data from...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors
March 16, 2022
- Represents Sonnet's first IND cleared - Phase 1 trial initiation expected in 2Q22 PRINCETON, NJ / ACCESSWIRE / March 16, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Exposures
Product Safety
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting
February 09, 2022
PRINCETON, NJ / ACCESSWIRE / February 9, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update
February 08, 2022
- SON-1010 and SON-080 on track to initiate clinical studies during the second quarter of 2022 - Completed R&D manufacturing for SON-1210 non-GLP toxicity study in non-human primates, with study...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Exposures
Product Safety
Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update
December 17, 2021
PRINCETON, NJ / ACCESSWIRE / December 17, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410)
August 30, 2021
- SON-1410 (IL18-FHAB-IL12), a bispecific combination of Interleukins 18 and 12, was selected based on data generated in a mouse melanoma study comparing three bispecific constructs - Selection of the...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering
August 19, 2021
PRINCETON, NJ / ACCESSWIRE / August 19, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update
August 16, 2021
Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update - Expanded F H AB Intellectual Property Portfolio - Completed $15.9 million At-The-Market Financing -...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Sonnet BioTherapeutics Announces Change in Date of Annual Meeting
June 14, 2021
- Annual Meeting to be Held Thursday July 15, 2021. PRINCETON, NJ / ACCESSWIRE / June 14, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology
June 08, 2021
U.S. Patent and Trademark Office issued US Patent No. 11,028,166 for the Company's Fully Human Albumin Binding Domain Fusion Proteins PRINCETON, NJ / ACCESSWIRE / June 8, 2021 / Sonnet BioTherapeutics...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update
May 17, 2021
- SON-1010, fully-human IL-12 configured using FHAB platform, advancing towards IND submission - At-The-Market offering program resulted in net proceeds of $10.2 million PRINCETON, NJ / ACCESSWIRE /...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)
May 10, 2021
- The No Observed Adverse Event Level (NOAEL) following repeated administration was more than 50 times the anticipated equivalent human clinical dose in NHP with no evidence of cytokine release...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Exposures
Product Safety
Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics
May 03, 2021
- New Life Therapeutics (NLT) to develop low-dose Interleukin 6 for Diabetic Peripheral Neuropathy in ASEAN territories - Upfront and potential milestone payments totaling up to $21 Million with up to...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.